Usted está aquí
Sagetis Biotech receives the advanced therapy designation from the EMA
Sagetis Biotech, a member of CataloniaBio, has received the Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency (EMA) for its novel polymer-coated adenovirus SAG 101 for the treatment of pancreatic ductal adenocarcinoma. Sagetis Biotech is developing an innovative gene delivery technology to overcome safe and effective delivery vectors.
The committee for advanced therapies is the EMA responsible for assessing the quality, safety and efficacy of ATMP products and this entitiy is who granted SAG 101 to the company for meeting the established standards for gene therapy, that consists on the insertion of genetic elements as vectors in the genome of the individual, to treat an illness.
Eduard Diviu, co-founder and CEO of Sagetis Biotech, commented "this represents a further step in the development of this unique class of virotherapy for oncology treatments”.
More information is available on the Sagetis Biotech website.